ProQR Therapeutics (NASDAQ:PRQR) Rating Increased to Buy at Citigroup

Citigroup upgraded shares of ProQR Therapeutics (NASDAQ:PRQR) from a neutral rating to a buy rating in a research report report published on Monday, MarketBeat.com reports. Citigroup currently has $4.00 price objective on the biopharmaceutical company’s stock.

Other analysts have also recently issued reports about the stock. Chardan Capital restated a “buy” rating and set a $4.00 price target on shares of ProQR Therapeutics in a report on Thursday, December 12th. HC Wainwright reissued a “buy” rating and set a $10.00 target price on shares of ProQR Therapeutics in a research note on Thursday, December 12th. Oppenheimer assumed coverage on shares of ProQR Therapeutics in a report on Friday, January 10th. They set an “outperform” rating and a $15.00 price target on the stock. JMP Securities reiterated a “market outperform” rating and set a $8.00 price objective on shares of ProQR Therapeutics in a report on Thursday, December 12th. Finally, StockNews.com downgraded ProQR Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 28th. One equities research analyst has rated the stock with a sell rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $9.17.

ProQR Therapeutics Trading Down 5.2 %

NASDAQ:PRQR opened at $1.81 on Monday. ProQR Therapeutics has a 1-year low of $1.61 and a 1-year high of $4.62. The firm has a market capitalization of $147.84 million, a price-to-earnings ratio of -5.66 and a beta of 0.24. The business’s fifty day moving average price is $2.32 and its 200 day moving average price is $2.63.

Hedge Funds Weigh In On ProQR Therapeutics

Several hedge funds have recently bought and sold shares of the business. OneDigital Investment Advisors LLC increased its holdings in shares of ProQR Therapeutics by 37.0% during the 3rd quarter. OneDigital Investment Advisors LLC now owns 57,550 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 15,550 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in ProQR Therapeutics by 14.2% during the third quarter. BNP Paribas Financial Markets now owns 58,801 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 7,300 shares during the last quarter. Ballentine Partners LLC acquired a new position in ProQR Therapeutics during the fourth quarter valued at approximately $61,000. M&T Bank Corp bought a new position in shares of ProQR Therapeutics in the fourth quarter valued at approximately $330,000. Finally, Raymond James Financial Inc. acquired a new stake in shares of ProQR Therapeutics in the fourth quarter worth $260,000. 32.65% of the stock is owned by institutional investors and hedge funds.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).